NATUREX SOCIETE ANONYME – Trademark Portfolio

Entity Type: 11

NATUREX SOCIETE ANONYME holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include KAVAPURE. The owner is based in MONTFAVET, AVIGNON F-84140.

ZAC POLE TECHNOLOGIQUE AGROPARC

MONTFAVET, AVIGNON F-84140 , FR

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

NATUREX SOCIETE ANONYME's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does NATUREX SOCIETE ANONYME have?

NATUREX SOCIETE ANONYME has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 cancelled.

What trademark classes does NATUREX SOCIETE ANONYME file in?

NATUREX SOCIETE ANONYME files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are NATUREX SOCIETE ANONYME's most well-known trademarks?

NATUREX SOCIETE ANONYME's registered trademark portfolio includes well-known marks such as KAVAPURE. These are among 1 currently registered trademark in the portfolio.

What is NATUREX SOCIETE ANONYME's trademark registration success rate?

NATUREX SOCIETE ANONYME has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.